JAN 07, 2013
Bausch & Lomb
Bausch & Lomb today announced it has obtained the exclusive global license for a new low-dose brimonidine formulation for hyperemia from Delaware-based startup Eye Therapies, LLC.
"The new low-dose brimonidine formulation appears to provide greater microvessel constriction at mucosal surfaces and is thought to retain more optimal blood flow from larger feeder vessels," said Mark B. Abelson, MD, CM, FRCS, FARVO, clinical professor of ophthalmology at Harvard Medical School and senior clinical scientist at Schepens Eye Research Institute.
A phase 2 study concluded the treatment appeared effective in reducing ocular redness based on both clinician assessment and patient reporting. There was no rebound vasoconstriction. Action began within five minutes and lasted at least four hours, with no serious adverse events.
Eye Therapies, a privately held biopharmaceutical company, developed the treatment in collaboration with Ora Inc., a private research organization.